Patients looking to save on antipsychotics have a new option. The patent protecting Johnson & Johnson’s blockbuster Risperdal expired yesterday, and today the FDA said it granted approval to Teva Pharmaceuticals to market the first generic version.
The Israeli generics maker was at the ready. “Shipping has commenced,” Teva spokeswoman Denise Bradley told the Health Blog.
Teva [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment